Want to see ICLR full AI Analyst Report?
ICLR Stock Chart & Stats
$170.02
$1.29(0.78%)
At close: 4:00 PM EDT
$170.02
$1.29(0.78%)
Day’s Range― - ―
52-Week Range$66.57 - $203.91
Previous CloseN/A
Volume71.62K
Average Volume (3M)727.07K
Market Cap
$12.33B
Enterprise Value$16.04K
Total Cash (Recent Filing)$928.38M
Total Debt (Recent Filing)$3.49B
Price to Earnings (P/E)38.1
Beta0.95
Next Earnings
Oct 28, 2026EPS Estimate
2.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.29
Shares Outstanding77,154,205
10 Day Avg. Volume487,811
30 Day Avg. Volume727,070
Financial Highlights & Ratios
PEG Ratio-0.90
Price to Book (P/B)1.55
Price to Sales (P/S)1.73
P/FCF Ratio16.58
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$187.92Price Target Upside10.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)10.6
Revenue Forecast (FY)$8.13B
Bulls Say, Bears Say
Bulls Say
Backlog And BookingsStrong bookings and a $23.4 billion backlog provide multi-period revenue visibility for a fee-based CRO. Sustained demand and new-customer wins can support utilization and future conversion, reducing reliance on a single quarter’s sales.
Cash GenerationRobust TTM operating and free cash flow, with strong conversion from earnings, gives ICON internal funding capacity for operations, investment and debt service. This supports resilience through changes in trial timing and working-capital cycles.
Global Service PlatformICON’s 40,200-person presence across 55 countries and broad service portfolio create a scalable platform for complex global trials. This breadth can deepen sponsor relationships, support cross-selling and strengthen its position with large life-sciences customers.
Bears Say
Margin PressureGross margin has declined from 2023–2024 levels, operating profitability compressed versus 2024, and 2025 net margin fell sharply. Persistent mix or cost pressure could limit the conversion of strong bookings into durable earnings and cash returns.
Uneven Revenue GrowthRevenue growth has been uneven: 2025 was flat to slightly down, while Q2 2026 rose only 1.2% year over year and adjusted profitability declined. This mismatch raises execution and demand-conversion risk despite strong order intake.
Debt Service BurdenNet debt remained $2.5 billion, or 1.8x adjusted EBITDA, after refinancing secured borrowings with senior unsecured notes. Ongoing debt service and refinancing obligations may constrain flexibility if profitability or cash conversion weakens.
ICLR FAQ
What was Icon plc’s price range in the past 12 months?
Icon plc lowest stock price was $66.57 and its highest was $203.91 in the past 12 months.
What is Icon plc’s market cap?
Icon plc’s market cap is $12.33B.
When is Icon plc’s upcoming earnings report date?
Icon plc’s upcoming earnings report date is Oct 28, 2026 which is in 54 days.
How were Icon plc’s earnings last quarter?
Icon plc released its earnings results on Jul 29, 2026. The company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.545 by $0.015.
Is Icon plc overvalued?
According to Wall Street analysts Icon plc’s price is currently Undervalued.
Does Icon plc pay dividends?
Icon plc does not currently pay dividends.
What is Icon plc’s EPS estimate?
Icon plc’s EPS estimate is 2.68.
How many shares outstanding does Icon plc have?
Icon plc has 77,154,205 shares outstanding.
What happened to Icon plc’s price movement after its last earnings report?
Icon plc reported an EPS of $2.56 in its last earnings report, beating expectations of $2.545. Following the earnings report the stock price went down -7.1%.
Which hedge fund is a major shareholder of Icon plc?
Currently, no hedge funds are holding shares in ICLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Icon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$187.92 (10.53% Upside)
$187.92 (10.53% Upside)
Blogger Sentiment
Bullish
ICLR Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 292.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Icon plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
ICLR Company Deck
ICLR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but stable picture: strong commercial momentum — including robust gross bookings (+22% YoY), hefty net wins (+42% YoY), higher book-to-bill (1.42x) and strategic commercial and digital initiatives — offset by notable margin compression year-over-year, pass-through volatility, and muted revenue growth on a constant currency basis. Management reiterated full-year guidance, highlighted balance sheet improvement and free cash flow generation, and outlined concrete actions and investments to drive margin recovery and long-term growth.View all ICLR earnings summariesICLR Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$187.92
▲(10.53% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Charles River Labs
―
Labcorp Holdings
―
Thermo Fisher
―
IQVIA Holdings
―
Medpace Holdings
―
Ownership Overview
0.06% Insiders
36.67% Mutual Funds
55.63% Other Institutional Investors
5.22% Public Companies and
Individual Investors










